目的:构建抗HER2重组融合蛋白基因ScFv/tBid,并探讨其对骨肉瘤E10细胞的促调亡作用。方法:通过间接免疫荧光染色、流式细胞仪(FCM)检测E10细胞膜表面HER2的表达。将抗HER2单链抗体基因e23sFv与铜绿假单胞菌外毒素PE的转膜结构域基因(PE...目的:构建抗HER2重组融合蛋白基因ScFv/tBid,并探讨其对骨肉瘤E10细胞的促调亡作用。方法:通过间接免疫荧光染色、流式细胞仪(FCM)检测E10细胞膜表面HER2的表达。将抗HER2单链抗体基因e23sFv与铜绿假单胞菌外毒素PE的转膜结构域基因(PEⅡ)和tBid基因连接,构建抗HER2重组融合蛋白基因ScFv/tBid,将其克隆入真核表达载体pCMV中构建重组pCMV-ScFv/tBid载体,转染骨肉瘤E10细胞。间接免疫荧光法检测目的蛋白表达和细胞形态学变化,Annexin V染色流式细胞术及TUNEL法检测E10细胞的凋亡情况。结果:流式细胞仪检测到E10细胞膜表面有HER2的表达。成功构建重组融合蛋白基因质粒pCMV-ScFv/tBid。重组质粒转染E10细胞后,间接免疫荧光双标记染色检测到E10细胞中tBid的过表达;细胞色素C在细胞质中出现;细胞出现明显的固缩、核浓缩等形态特征。Annexin V染色后流式细胞仪检测可见实验组细胞凋亡率较对照组明显升高(16.1% vs 4.5%);TUNEL染色显示,E10细胞出现典型的凋亡特征。结论:重组抗HER2融合蛋白基因ScFv/tBid可以在转染的骨肉瘤E10细胞中表达,并诱导骨肉瘤细胞发生凋亡。展开更多
Latency is the pivotal factor that governs the long-term pathogenecity and persistence of HIV-1 infection.It is also the primary impediment to cure and successful treatment,resulting in patient death.Latency of HIV-1 ...Latency is the pivotal factor that governs the long-term pathogenecity and persistence of HIV-1 infection.It is also the primary impediment to cure and successful treatment,resulting in patient death.Latency of HIV-1 infection promotes failure of the conventional antiretroviral therapy(ART).Cessation of ART immediately leads to viral reactivation and attainment of viral load in peripheral circulation.ART comes with severe side effects and is ineffective at treating latent infection.To eliminate latent infection,alternate therapeutic strategies such as Shock and Kill,Block and Lock,gene editing and vaccination have been proposed.Although these strategies have experimentally been proven successful,they possess major limitations.Hence,in this hypothesis,an alternate therapeutic strategy has been proposed to solve the threat of HIV-latency.The proposed model encompasses the generation and administration of recombinant HIV-1 particles whose genomes having pro-apoptotic gene,tBid,will activate apoptotic cell death pathways after infecting only the latent cells,thereby removing latent HIV host cells from patients’bodies.展开更多
文摘目的:构建抗HER2重组融合蛋白基因ScFv/tBid,并探讨其对骨肉瘤E10细胞的促调亡作用。方法:通过间接免疫荧光染色、流式细胞仪(FCM)检测E10细胞膜表面HER2的表达。将抗HER2单链抗体基因e23sFv与铜绿假单胞菌外毒素PE的转膜结构域基因(PEⅡ)和tBid基因连接,构建抗HER2重组融合蛋白基因ScFv/tBid,将其克隆入真核表达载体pCMV中构建重组pCMV-ScFv/tBid载体,转染骨肉瘤E10细胞。间接免疫荧光法检测目的蛋白表达和细胞形态学变化,Annexin V染色流式细胞术及TUNEL法检测E10细胞的凋亡情况。结果:流式细胞仪检测到E10细胞膜表面有HER2的表达。成功构建重组融合蛋白基因质粒pCMV-ScFv/tBid。重组质粒转染E10细胞后,间接免疫荧光双标记染色检测到E10细胞中tBid的过表达;细胞色素C在细胞质中出现;细胞出现明显的固缩、核浓缩等形态特征。Annexin V染色后流式细胞仪检测可见实验组细胞凋亡率较对照组明显升高(16.1% vs 4.5%);TUNEL染色显示,E10细胞出现典型的凋亡特征。结论:重组抗HER2融合蛋白基因ScFv/tBid可以在转染的骨肉瘤E10细胞中表达,并诱导骨肉瘤细胞发生凋亡。
文摘Latency is the pivotal factor that governs the long-term pathogenecity and persistence of HIV-1 infection.It is also the primary impediment to cure and successful treatment,resulting in patient death.Latency of HIV-1 infection promotes failure of the conventional antiretroviral therapy(ART).Cessation of ART immediately leads to viral reactivation and attainment of viral load in peripheral circulation.ART comes with severe side effects and is ineffective at treating latent infection.To eliminate latent infection,alternate therapeutic strategies such as Shock and Kill,Block and Lock,gene editing and vaccination have been proposed.Although these strategies have experimentally been proven successful,they possess major limitations.Hence,in this hypothesis,an alternate therapeutic strategy has been proposed to solve the threat of HIV-latency.The proposed model encompasses the generation and administration of recombinant HIV-1 particles whose genomes having pro-apoptotic gene,tBid,will activate apoptotic cell death pathways after infecting only the latent cells,thereby removing latent HIV host cells from patients’bodies.
